In the neoadjuvant setting, HER2 discordance refers to the loss of HER2 expression or amplification in residual tumor found at surgery compared with the initial biopsy after intervening neoadjuvant HER2‐directed therapy. The gene discussed is ERBB2; the disease is neoplasm.